In contrast, aberrant signalling has also been linked to vascular disorders such as hypertension, atherosclerosis and coronary heart diseases and has also been shown to occur during sepsis and neurodegenerative disorders.1,2 From a drug design perspective, sGC is an attractive target for small molecule modulators and activators are currently under clinical development for the treatment of cardiovascular diseases.3,4 sGC is generally found as a heterodimer composed of a β-subunit (70 kDa) and a larger α-subunit (82 kDa). The gene discussed is SGCB; the disease is cardiovascular disorder.